daily of Akurit-4 (Rifampicin 150mg, Isoniazid 75mg, Pyrazinamide 400mg, Ethambutol 275mg) was presented on the 6 th week into the intensive phase of his anti-TB treatment with fever and myalgia for a few days duration. His vital signs were stable, and systemic examinations were unremarkable except for reduced vesicular breath sounds over left basal lung. Initial blood investigations were taken (as shown in Table 1 ). He was treated as viral fever and was admitted for observation. On day 6 of admission, he developed a spike of high-grade fever. His chest symptom was worsening, and the radiograph imaging of the chest showed presence of pneumonitis with unchanged cavitating lesion (as shown in Figure 1 ). He was then subjected to contrast-enhanced computed tomography scan of the thorax and it showed thickwalled cavitating lesion with associated lung nodule, bronchiectatic changes, tree in bud appearance and mediastinal lymphadenopathy. It also shows finding consistent of a tuberculosis (as shown in Figure 2 ). He was started on intravenous (IV) Ceftriaxone 1gm once daily in addition to the Aquarit-4 to cover for infective pneumonitis, which later was switch to IV Tazobactam 500mg and Piperacillin 4gm six hourly after 3 days as there was no improvement. Subsequently, he developed transaminitis, and also a maculopapular rash which started over the neck region and moved down to the trunk and both lower limbs with total of 40% body surface area involved. Drug rash was suspected and the IV antibiotic was discontinued. However, despite discontinuing the antibiotics, the rash persisted and his blood investigations trend showed worsening transaminitis and increasing trend of eosinophilia and lymphocytosis (as shown in Table 2 ). In view of the haematological abnormalities in addition to transaminitis and pneumonitis which signify multiorgan involvement, drug reaction with eosinophilia and systemic symptoms syndrome secondary to the Akurit-4 was suspected. Therefore, the Akurit-4 was withhold, and oral prednisolone 25mg once daily was started. The fever and maculopapular rash subsided. Later on, he was given with second line anti-tuberculosis treatment consist of streptomycin, ethambutol and moxifloxacin. Upon discharge, patient clinically well and the haematological abnormalities slowly went back to normal. The oral prednisolone dose was gently tapered down at 5mg every week.
DISCUSSION
Anti-tuberculosis drugs are known to cause several side effects, such as peripheral neuropathy, liver toxicity, optic neuritis, precipitation of gout, just to name a few. It also known to cause hypersensitivity reaction in some patients. However, it is not common to cause hypersensitivity reaction with multi organ involvement, a syndrome that is called drug reaction with eosinophilia and systemic symptoms (DRESS). DRESS syndrome is a potentially life-threatening hypersensitivity condition that usually under-unexpected and presents within 8 weeks of initiation of the causative medication. Aromatic anticonvulsants such as phenytoin, phenobarbital and carbamazepine are the most common triggers, but other drugs such as allopurinol, minocycline, dapsone, sulfasalazine, and mexiletine have also been reported to be associated with DRESS syndrome. Fever is the most common feature and may precede the skin eruption.
2 Skin eruption starts as a morbilliform rash that progress to confluent, diffuse and generalised into erythroderma with follicular attenuation. The face and upper part of the trunk and extremities are involved first. Periorbital and facial oedema occur in 25% of cases and usually is symmetrical, persistent and associated with erythema and nearly half of patients have inflammation and pain of mucous membrane most often the mouth or pharynx and does not progress to erosion. In DRESS syndrome, the eruption typically involves more than 50% of the body surface area. Haematological abnormalities found in 50% of cases and includes thrombocytopaenia, eosinophilia, leucocytosis, haemolytic anaemia and atypical lymphocytes. Internal organ involvement includes elevated liver enzymes, hepatitis and liver necrosis and other fatal complications such as pericarditis, pneumonitis, nephritis, pancreatitis, colitis, myositis and meningitis. 3 Treatment of DRESS syndrome generally consist of withdrawal of the offending drugs, correction of electrolytes imbalance, and administration of steroid. High potency topical corticosteroid can be given for symptomatic relieve in patients without organ involvement. In those with organ involvement, systemic corticosteroids have become a mainstay of therapy in the form of prednisolone. It often produces dramatic improvement in clinical symptoms and laboratory measures in just a few days after the initiation of treatment. 4 The prednisolone dose will be tapered down slowly over course of 8 to 12 weeks as rapid tapering may increase the risk of relapse. If symptoms continue to progress despite the use of corticosteroids, other options include intravenous immunoglobulin or plasmapheresis. 5 Other non-steroidal immunosuppressive agents have been reported to show a promising treatment effectiveness. 6 However, further studies are required to establish the benefits of these immunosuppressants as the number of patients receiving these treatments are very limited. DRESS syndrome has mortality rate of around 10%. 7 The damage to organs can be severe and permanent. Fortunately, most affected patients will recover completely in weeks to months after causative drug withdrawal. 8 The diagnosis of DRESS syndrome tends to be missed or delayed as a result of the nature of its presentation which highly variable. Our patient developed DRESS syndrome on the 6 th week of his intensive phase of anti-tuberculosis treatment with Akurit-4 with the clinical manifestations of fever, pneumonitis, hepatitis and other deranged laboratory investigations that mimic those of a severe superimposed infection. As the patient did not respond to two types of intravenous antibiotics and also with the development of maculopapular rash and progressive transaminitis, eosinophilia and lymphocytosis, it raised the suspicion of DRESS syndrome. The patient shows a dramatic response upon withdrawal of Akurit-4 and oral systemic steroids. Apart from the difficulty to recognize the syndrome, one other major challenge faced in managing this patient was the decision to withdraw the first line anti-tuberculosis treatment and the initiation of second line medication in which fortunately the patient responded without any difficulty.
In conclusion, this case report served to share an uncommon occurrence of DRESS syndrome secondary to anti-TB medications, and to emphasize the importance of having high suspicion level to avoid diagnostic delay for this severe drug reaction has significant mortality rate and potentially treatable with prompt withdrawal of the offending drugs and initiation of systemic steroids. However, clinical judgement has to be made from case to case basis in order to differentiate this condition from those caused by infections.
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